It's How Medicine Should Be®


French German Italian Portuguese Russian

NSCLC Subject Treatment Study

Clinical Trial Title: 
A phase II/III randomized trial of two doses of MK-3475 versus Docetaxel in previously treated subjects with NSCLC
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Jo Fidler, MD
Clinical Trial Protocol Description: 

Treatment of subjects with NSCLC whose tumors are positive for PD-L1 and have experienced disease progression after a platinum-containing systemic treatment. The purpose of this study is to test the safety and tolerability of the research study drug MK-3475 and to test the effectiveness of the study drug to standard care Docetaxel. Nationwide, 520 to 920 patients will be recruited for this study. At Rush University Medical Center, we expect to recruit approximately 10 patients.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have stage IIIb or IV NSCLC with positive PD-L1.
  • Have progressed with platinum-containing treatment.
  • Must know or have tissue tested for EGFR and ALK mutation. If EGFR+ - must have also been on a EGFR tyrosine kinase inhibitor. If ALK+ - must have been on crizotinib.

You will be excluded from the study if any of the following criteria apply to you:

  • Have received prior treatment with Docetaxel for NSCLC.
  • Have had a previous malignancy within the past five years (exception — basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer).
  • Have active or a history of autoimmune disease.
  • Have a history of organ transplant.
  • Are pregnant or lactating.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Phone: 
(312) 942-2364
Contact Name: 
Andrea Glidden